Dialysis and ESRD Claims in 2026 Self-Funded Health Plans

For a self-funded employer, few claims reshape a plan year the way a single case of end-stage renal disease can. Dialysis is among the most concentrated and expensive exposures a health plan carries — and, unlike the catastrophic cancer claim that arrives without warning, it comes with a cost curve the plan can see forming years in advance. That visibility is precisely why dialysis rewards a plan that prepares and quietly punishes one that does not.

The numbers explain the stakes. Research published in the American Journal of Managed Care found that annual all-cause costs climb exponentially with kidney disease stage — from roughly $7,537 for a commercially insured patient with no chronic kidney disease, to nearly $76,969 at stages four and five, to about $121,948 once the patient reaches end-stage renal disease. Dialysis alone runs near $120,000 a year for a commercial patient, roughly four times the $29,000 Medicare pays for the same treatment. The gap is not clinical — it is the price a self-funded plan pays for the identical care.

And these claims are multiplying. Sun Life, analyzing more than 70,000 high-dollar claims from over 3,300 self-funded employers, reports that million-dollar claims rose 46 percent in frequency between 2022 and 2026, with kidney and renal conditions among the recurring high-cost drivers. Segal's 2026 data shows medical stop-loss premiums rising nearly 13 percent as the shock losses that were once rare become routine. A dialysis claimant is no longer an outlier a plan absorbs once a decade — it is a line item a disciplined plan designs around.

The structure of the exposure is what makes it manageable. Federal law, through the Medicare Secondary Payer Act, requires a group health plan to remain the primary payer for the first 30 months after an ESRD diagnosis, with Medicare stepping in only afterward. That 30-month window — the most expensive stretch of the claim — lands squarely on the plan. End-stage renal disease is also one of the few conditions that qualifies a person for Medicare regardless of age, which is precisely why the coordination rules, and the long-running fight over plans steering patients toward Medicare, exist in the first place. Understanding exactly where that coordination begins and ends is the difference between a plan that anticipates the cost and one that discovers it mid-year.

The Supreme Court handed self-funded plans a real lever here. In Marietta Memorial Hospital v. DaVita, decided 7 to 2 in June 2022, the Court held that a plan may set low, uniform dialysis reimbursement — and treat all dialysis as out-of-network — without violating the Medicare Secondary Payer Act, provided the same terms apply to every participant. As SHRM and the National Law Review both noted, the decision gave plans genuine room to contain dialysis cost. But the protection lives in the uniformity: the terms must be drafted into the plan document with care and applied evenly, or the advantage the ruling offers is forfeited.

The reason the lever matters is market structure. Two organizations dominate U.S. dialysis, and Health Affairs has documented the substantial markups consolidated dialysis providers command from commercial payers. A single employer negotiating alone against that concentration is outmatched. The disciplined responses — reference-based pricing for dialysis, specialized carve-out vendors, and dedicated case management — all depend on plan-document language written before the claim, not after the first invoice arrives.

This is where the financing structure earns its place. A dialysis claim is exactly the recurring, high-cost shock loss that tests a stop-loss program, and it is the kind of volatility a group captive is built to absorb. Pooling that risk lets a mid-market employer fund the predictable layer, share in favorable experience, and transfer the catastrophic tail — rather than watching a single claimant consume a year of margin. The question is never whether to cover dialysis; it is how to structure reimbursement, the stop-loss attachment point, and the plan document so the exposure is owned on purpose.

This is the work of PFTN's 4-Step Strategic Process. Strategic Discovery surfaces the plan's real claim concentration and where renal risk already sits in the population. Risk Assessment measures the dialysis exposure against the plan's reimbursement terms, stop-loss attachment, and the 30-month coordination window. Solution Design crafts the plan-document language, pricing approach, and captive or stop-loss structure that fit the workforce. Ongoing Optimization keeps the design honest as claims, case law, and dialysis pricing evolve.

Dialysis is the rare catastrophic cost a self-funded employer can see coming. Illuminating the exposure — its price, its 30-month window, the reimbursement lever the courts have allowed, and the captive structure that carries the volatility — turns a claim that could rewrite a plan year into one the employer has already decided how to own.